Drug and Therapeutics Bulletin 2001;39:68-72; doi:10.1136/dtb.2001.39968
Copyright © 2001 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Bisphosphonates for osteoporosis

Relevant BNF section: 6.6.2

One in three women and at least one in 12 men in the UK have osteoporosis, a condition which can lead to fractures, deformity, pain and disability, at a cost to the NHS of around £1.5 billion each year.^1,2 Bisphosphonates offer a therapeutic option for preventing and treating osteoporosis. Here, we assess and compare the three bisphosphonates (alendronate, etidronate and &#9660risedronate*) licensed for such use in the UK. We do not consider the four bisphosphonates (clodronate, pamidronate, tiludronate and &#9660zoledronate) that are licensed in the UK only for the treatment of Paget's disease of bone and/or hypercalcaemia of malignancy.

This article has been cited by other articles:

				D. G. Jones, R. Savage, and J. Highton Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome BMJ, January 8, 2005; 330(7482): 74 - 74. [Full Text] [PDF]

				F. Saad Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go? J Natl Cancer Inst, September 3, 2003; 95(17): 1262 - 1263. [Full Text] [PDF]